The RegIntelHub Weekly

Global PV updates, distilled - powered by our community

A quieter week on the surface - but not insignificant. The EU PV landscape is as vibrant as ever, so make sure you read this issue to stay aligned with changes unfolding over the next few years.

As always, thank you to everyone who shared links, documents, and local insights by email or in Slack - this newsletter exists because of you 🙏

👇 Start with the 10-Second Summary, then dive deeper if something touches your portfolio.

⏱️ 10-Second Summary (Read This First)

If you read nothing else this week:

🇪🇺 EU — Political agreement reached on the new EU pharmaceutical legislation.
🇪🇺 EU — Implementing Regulation (EU) 2025/1466 fully applicable from 12 Feb 2026.
🇬🇧 Northern Ireland — Updated MHRA guidance on EU MDR/IVDR application in NI.

Details and links below 👇

👀 This Period's Highlights

🇪🇺 EU — Reform of the EU Pharmaceutical Legislation​

On 11 December 2025, political agreement was reached on the biggest overhaul of EU pharmaceutical legislation in over 20 years.

The reform will revise and replace:

• Regulation (EC) 726/2004
• Directive 2001/83/EC
• Paediatric Regulation (1901/2006)
• Orphan Regulation (141/2000)

And amend:

• ATMP Regulation
• Clinical Trials Regulation
• EMA Extended Mandate Regulation

What this means for you:

Nothing changes operationally today — but mark this timeline:

• 2026 → Final legal texts adopted and enter into force
• 2026–2028 → Transition phase

• Member States update national laws
• Commission adopts implementing/delegated acts
• EMA & NCAs adapt guidance and IT systems

•2028 → New framework becomes applicable

This is a strategic roadmap item, not an immediate SOP update.

🇪🇺 EU — Implementing Regulation (EU) 2025/1466 Now Fully Applicable

As of 12 February 2026, this regulation is fully enforceable. Inspectors can now assess against it.

The two changes you should keep front of mind:

Signal Management — EudraVigilance Embedded

From August 2025 onward:

• Routine monitoring of EudraVigilance is mandatory
• Standalone signal notifications to EMA are discontinued
• Signal evaluation is embedded within PRAC processes

Signal workflows must now clearly demonstrate integration with EV data and PRAC outcomes.

Outsourcing & Vendor Governance

MAHs retain full responsibility for:

• All third-party PV activities
• Subcontracting chains
• Audit planning and execution

No uncontrolled further delegation.
​Risk-based PV audits are now explicitly embedded in the legal framework.

If vendor oversight is weak, inspection risk increases.

🇬🇧 Northern Ireland — Updated Device Regulation Guidance​

MHRA updated guidance (12 February 2026) clarifying how EU MDR and IVDR apply in Northern Ireland.

This provides clearer direction on:

• Market access requirements
• Applicable EU frameworks
• Manufacturer and supplier responsibilities

If you place medical devices on the Northern Ireland market, double-check your regulatory positioning.

🗣️ Join the Conversation & Contribute

What did you think of this week’s edition? Was it helpful?
Hit reply to share your thoughts or tell us if we missed an update.

​
If you found this useful, please share it with one PV colleague or join our growing Slack workspace to discuss these changes.

Until next week - stay compliant, stay curious.

⚖️ Disclaimer
This newsletter is for informational purposes only and does not constitute professional or legal advice.
All summaries are based on publicly available regulatory information. Always verify requirements with the relevant authority or qualified professional before implementation.
RegIntelHub assumes no liability for actions taken based on this content.